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Abstract
The thymidine analogue 4-thiothymidine (S4TdR) is a
photosensitizer for UVA radiation. The UV absorbance
spectrum of S4TdR and its incorporation into DNA
suggests that it might act synergistically with nonlethal
doses of UVA to selectively kill hyperproliferative or
cancerous skin cells. We show here that nontoxic
concentrations of S4TdR combine with nonlethal doses
of UVA to kill proliferating cultured skin cells. Established
cell lines with a high fraction of proliferating cells were
more sensitive than primary keratinocytes or fibroblasts
to apoptosis induction by S4TdR/UVA. Although S4TdR
plus UVA treatment induces stabilization of p53, cell
death, as measured by apoptosis or clonal survival, occurs
to a similar extent in both p53 wild-type and p53-null
backgrounds. Furthermore, different types of human
papilloma virus E6 proteins, which protect against UVB-
induced apoptosis, have little effect on killing by S4TdR/
UVA. S4TdR/UVA offers a possible therapeutic interven-
tion strategy that seems to be applicable to human
papilloma virus–associated skin lesions. [Mol Cancer Ther
2007;6(9):2487–95]
Introduction
Skin cancer is the most frequently diagnosed neoplastic
condition. The frequency of nonmelanoma skin cancer
(NMSC) in Caucasian populations has risen steadily in
recent years and is predicted to increase further (1–3).
Solar radiation is the major etiologic factor in the
development of the basal cell carcinomas and squamous
cell carcinomas (SCC) which comprise the majority of
NMSCs. A significant fraction of incident solar UVA
(wavelengths, 320–400 nm) and longer wavelength UVB
(290–320 nm) penetrates the epidermal layer into the
underlying dermis. These contain the keratinocytes and
fibroblasts, respectively. UV radiation also causes epider-
mal thickening, which protects the underlying cells. This
protective process can be compromised in hyperprolifer-
ative skin lesions.
DNA damage is firmly implicated in the initiation of
NMSC. The DNA cyclobutane pyrimidine dimers and
(6-4)pyrimidine-pyrimidone photoproducts that are gener-
ated when DNA absorbs UVB (4) are associated with
mutagenesis and cancer. The p53 tumor suppressor gene is
commonly mutated in SCC, and the most frequent p53
mutations are transitions at dipyrimidine sites that are
considered signatures for UV-induced DNA damage.
Individuals with xeroderma pigmentosum, in whom the
nucleotide excision repair pathway is disabled by mutation,
are unable to remove mutagenic DNA photoproducts from
their skin cells and have a greatly (2,000-fold) increased rate
of skin cancer in sun-exposed areas (5). Although UVA is
the main component of incident sunlight, it is less directly
damaging to DNA because the constituent purine and
pyrimidine bases do not absorb significantly at wave-
lengths >320 nm. The genotoxic effects of UVA are a
consequence of indirect photochemical reactions and it is
less mutagenic and carcinogenic than UVB.
There is mounting evidence that human papilloma
viruses (HPV) are a cofactor with UV in the development
of NMSC (6). HPVs infect keratinocytes, alter the rate of
epithelial proliferation and interfere with normal differen-
tiation (7–9). As a result, the natural barrier formed by the
upper layers of the epidermis is weakened. Although
cutaneous HPV infection is usually a benign, self-limiting
process, it may occasionally be associated with malignant
conversion (10). The involvement of HPV in anogenital
cancer is widely acknowledged (11). The E6 and E7
proteins encoded by anogenital HPV types 16 and 18
inactivate the p53 and Rb proteins that are critical for an
appropriate cellular response to DNA damage. There is a
noteworthy association between HPV and skin tumors in
immunosuppressed renal transplant recipients and
patients with the rare genetic disorder epidermodysplasia
verruciformis (6, 10, 12, 13). Individuals with epidermo-
dysplasia verruciformis develop SCC on sun-exposed parts
of the body and these tumors are frequently host to HPV5
or HPV8 (14, 15). Because of this, HPVs, notably HPV5 and
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HPV8, have become a major focus of investigations in
NMSC. The E6 and E7 proteins from cutaneous HPVs do
not seem to compromise p53 or Rb function in the same
way as the anogenital HPV E6 proteins. However, they do
inhibit UVB-mediated, p53-dependent apoptosis (16). Cer-
tain HPV types selectively inhibit p53-dependent transcrip-
tion of proapoptotic genes (17). Others may delay the repair
of UVB-induced thymine dimers (18). Importantly, the E6
protein of cutaneous HPVs can target the mitochondrial
Bcl-2 homologous antagonist/killer (Bak) protein—a key
regulator of apoptosis—for proteolytic degradation (19).
The consequent abrogation of UVB-induced apoptosis may
contribute to NMSC development.
Surgical excision is the most common and successful
treatment for localized primary skin lesions. Alternative
approaches such as electrodessication, curettage and
cryosurgery, or radiotherapy offer poor cosmetic outcome.
Phototherapy is also a treatment option. Therapeutic UVB
and psoralen plus UVA light are used to treat inflammatory
dermatoses such as psoriasis. In psoralen plus UVA, a
nontoxic photoreactive drug is activated by subsequent
exposure to UVA to cause extensive DNA damage that
eventually kills the tumor cells. Psoralen plus UVA has
been widely used to treat psoriasis (20) as well as head and
neck cancers. Although highly effective and well tolerated,
it has serious limitations. In particular, it involves high
cumulative doses of UVA and is associated with an
increased risk of NMSC (21, 22). Significantly, the effec-
tiveness of psoralen plus UVA is compromised in p53
mutant cells (23). This is particularly important because
>90% of skin tumors contain p53 mutations (24, 25). In
addition, if apoptotic pathways under the control of Bak are
involved in the toxicity of antitumor treatments, infection
by HPVs of the epidermodysplasia verruciformis type may
compromise therapeutic effectiveness. For this reason,
there is a need to develop alternative ways to kill hyper-
proliferative skin cells.
The nontoxic thiopyrimidine nucleoside, 4-thiothymidine
(S4TdR), was previously shown to sensitize established
human cell lines to low doses of UVA (f365 nm; ref. 26).
S4TdR/UVA toxicity depends absolutely on S4TdR salvage
by thymidine kinase and incorporation into DNA. We have
examined cell killing by the S4TdR/UVA combination in
more detail. In particular, we address the possible suitability
of S4TdR/UVA as an intervention strategy in epidermal
disease, including NMSC and whether it might evade the
antiapoptotic action of HPV in virally infected cells.
Materials andMethods
Cells and Cell Culture
Cells were all grown in 10% CO2 at 37jC and media
supplemented with 10% FCS. HT1080 fibrosarcoma cells
which express both the codon 72 arginine and proline (arg/
pro) isoforms of wild-type p53 (27), normal, and psoriatic
human skin fibroblasts were grown in DMEM. RTS3b, a
spontaneously immortalized p53-null keratinocyte cell line
(28) was grown in DMEM/Ham’s F12 (3:1) plus growth
factors and normal human keratinocytes in the same
medium on a feeder layer of gamma ray–irradiated (60
Gy) Swiss 3T3 fibroblasts (29). The normal skin fibroblasts
and keratinocytes were derived from a 46-year-old patient
following breast surgery (skin type I). All experiments with
keratinocytes and fibroblasts were done with cells at
passages 3 to 5. Stable polyclonal HT1080 cell lines
expressing E6 protein from either HPV5 or HPV18 in the
bicistronic vector pIres (Clontech) were generated and
expression of viral mRNA verified by RT-PCR as previ-
ously described (18). All studies involving patient material
were carried out with prior local ethics committee approval
and informed consent.
Chemicals and DrugTreatments
All chemicals, except where specified, were purchased
from Sigma Chemical Co. S4TdR was synthesized as
described previously (30) and dissolved in sterile deion-
ized water. All treatments with S4TdR were carried out for
48 h in medium containing 10% FCS which had been
dialyzed extensively through a 2-kDa exclusion mem-
brane Spectra/Por (Spectrum Laboratories; Medicell
International, Ltd.).
UVRadiation
UVA irradiation was delivered from a UVH 253 lamp
(UV Light Technology, Ltd.) with a maximum output of
100 mW/cm2, as described previously (26). Emission wave-
lengths ranged from320 to 400nmwith amaximumat 365 nm.
UVB radiation was delivered from a broadband CL-1000
(Ultra-violet Products, Ltd.) equipped with five F8T5 bulbs
giving a spectral peak at 312 nm. The outputwas 1.2mW/cm2.
Cells were irradiated at 60% to 70% confluency.
Determination of Cell Survival
Treated cells were plated at clonal density (20–40 cell/
cm2, depending on the cell type) in fresh growth medium
and allowed to attach for 4 to 8 h prior to irradiation. The
colony-forming efficiency of untreated cells was between
5% and 12%. Keratinocytes were plated onto lethally
gamma-irradiated Swiss 3T3 fibroblasts. After UVA irradi-
ation, cells were maintained in drug-free normal growth
medium for 10 to 14 days. Colonies were then fixed, stained
with crystal violet, and scored. For each determination, at
least three independent experiments were done in triplicate
dishes for each experimental point.
Dimethylthiazol-2-yl-2-5-Diphenyltetrazolium Bro-
mideAssays
Cells were seeded in 96-well plates in medium contain-
ing dialyzed serum and S4TdR (0, 10, 30, or 100 Amol/L)
for 48 h, then UVA- or UVB-irradiated. After irradiation,
normal growth medium was replaced and incubation
continued for 72 h. Cells were then incubated for 4 h
in dimethylthiazol-2-yl-2-5-diphenyltetrazolium bromide
solution (0.5 mg/mL) prepared in serum-free medium.
Medium was removed and DMSO was added to
solubilize the precipitate. Optical densities were mea-
sured at 570 nm.
Western Blot Analysis
Total cell lysates were resolved on SDS polyacrylamide
gels and transferred onto polyvinylidene difluoride
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membranes (Amersham). Membranes were probed with
primary antibodies against: p53 (DO-1, dilution 1:1,000;
Cancer Research UK), Bak (Ab-2, dilution 1:250 for Western
blots; Ab-1, dilution 1:50 for flow cytometry), Bax (2D2,
dilution 1:1,000), Mdm2 (IF2, dilution 1:1,000), and
a-tubulin (DM1A, dilution 1:4,000) from Calbiochem,
E6AP (BL447, dilution 1:1,000) from Bethyl Laboratories,
Inc., phospho-Ser15 (dilution 1:1,000), phospho-Ser392
(dilution 1:1,000) p53, p21 (DCS60, dilution 1:2,500), and
cleaved caspase 3 (Asp175, dilution 1:1,000) from Cell
Signaling Technology, Inc. Secondary antibodies were
horseradish peroxidase–conjugated rabbit anti-mouse or
goat anti-rabbit (used at dilution of 1:2,000; Dako UK, Ltd.).
Reactive proteins were visualized by chemiluminescence
with ECL plus (Amersham plc).
Flow Cytometry
Annexin V + propidium iodide (PI) staining. After UV
treatment, adherent and nonadherent cells were pooled
and treated with Alexa647-conjugated Annexin V (BD
Biosciences) in 10 mmol/L of HEPES-NaOH (pH 7.4), 140
mmol/L of NaCl, and 2.5 mmol/L of CaCl2 for 15 min at
room temperature in the dark. Following transfer to
ice, PI (at a concentration of 50 Ag/mL in PBS) was added
for 5 min and cells were analyzed by flow cytometry.
For analysis of S phase population by bromodeoxyuridine
labeling, S4TdR-treated cells were pulse-labeled with
bromodeoxyuridine (10 Amol/L) for 1 h at 37jC, harvested,
fixed with 70% ethanol, and processed for analysis by flow
cytometry. Flow cytometric detection of the open Bak
isoform was done as described elsewhere (31). For each
sample, 10,000 cells were analyzed and data were captured
on a FACSCalibur (BD Biosciences) and analysis was done
using CellQuest software (Becton Dickinson).
Microscopy
Cells were visualized on a Leica microscope (Leica
Microsystems UK, Ltd.), using bright-field setting and a
200 magnification.
Statistical Analysis
The results are represented as the mean F SD. Significant
differences (P < 0.05) are indicated and were determined by
Student’s t test, either paired or unpaired, after one-way
ANOVA (*, P < 0.05; **, P < 0.01).
Results
Cell Killing by S4TdR/UVA
Effect of Growth in S4TdR on Cell Cycle. S4TdR/UVA
was previously shown to be cytotoxic towards SV40-
transformed human fibroblast and lymphoma cell lines
(26). To examine the effects of S4TdR/UVA in cells more
relevant to human skin disorders, we compared the
responses of HT1080, fibrosarcoma cell line (27), and
RTS3b—a spontaneously immortalized keratinocyte cell
line (28). These cell lines were compared with primary
normal adult keratinocytes (normal human keratinocytes,
NHK) and their patient-matched dermal fibroblasts (nor-
mal human fibroblasts, NHF), and to cultures of primary
dermal psoriatic fibroblasts.
S4TdR/UVA toxicity depends on S4TdR incorporation
into DNA. To maximize incorporation, cells were grown in
medium containing S4TdR supplemented with FCS deplet-
ed of endogenous TdR by dialysis. Using flow cytometry,
we first examined whether this had a significant effect on
cell proliferation or on cycle distribution, as measured after
pulse-labeling with bromodeoxyuridine. Neither HT1080
nor RTS3b cells were affected by growth in dialyzed serum,
100 Amol/L of S4TdR, or both. Irrespective of the growth
conditions, approximately half of the cells (54–57%) were
in S phase (Supplementary Table S1).4
The cell cycle distributions of NHK and NHF from
normal adult skin differed substantially from those of the
two established cell lines. As expected, both NHK and
NHF contained a substantially lower fraction of S phase
cells (12–18%) and a proportional increase in G0/G1 cells
(62–79%). In NHK, neither of these variables were affected
by growth in dialyzed serum or S4TdR. In both NHF and
psoriatic human fibroblast, growth in dialyzed serum
caused a small (<2-fold) decrease in the fraction of S phase
cells. No detectable change in proliferative fraction oc-
curred in the presence of S4TdR, however (Supplementary
Table S1).4
Sensitization to UVA Killing. S4TdR sensitized both
HT1080 and RTS3b cells to low doses of UVA. Cells grown
for 48 h in a range of S4TdR concentrations were irradiated
with 5 or 10 kJ/m2 of UVA and sensitivity determined by
dimethylthiazol-2-yl-2-5-diphenyltetrazolium bromide as-
say. For both cell lines, survival was significantly reduced
by 10 Amol/L of S4TdR combined with 5 kJ/m2 of UVA
(Fig. 1). The same UVA dose was more toxic to both HT1080
and RTS3b cells that had been grown in 30 or 100 Amol/L of
S4TdR. Neither UVA (5 or 10 kJ/m2) nor S4TdR alone (10, 30,
100 Amol/L) detectably affected survival. In control experi-
ments, both cell lines were sensitive to UVB (0.15 kJ/m2)
independently of growth in S4TdR. This is consistent with
its lack of significant absorbance in the UVB region (26).
Over the range of S4TdR and UVA doses examined, HT1080
cells were slightly more sensitive than RTS3b. This was also
reflected in their similar slightly greater sensitivity to UVB.
Without the photosensitizer, neither the established cell
lines nor primary keratinocytes (NHK) or fibroblasts (NHF)
were significantly affected by UVA alone at doses <50 kJ/m2.
Above this dose, survival, measured by clonal assay,
declined. HT1080 and RTS3b were equally sensitive and
their survival was reduced tof10% at 200 kJ/m2 (Fig. 2A).
NHK were significantly more resistant to UVA than their
immortal RTS3b counterparts and NHF. Approximately
40% of NHK survived a dose of 200 kJ/m2 (Fig. 2A). NHF
were the most sensitive and only f1% survived a dose of
200 kJ/m2. This observation is consistent with the generally
decreased susceptibility of NHK to UV irradiation reported
by other laboratories (32).
4 Supplementary material for this article is available at Molecular Cancer
Therapeutics Online (http://mct.aacrjournals.org/).
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The ability of S4TdR to sensitize HT1080 and RTS3b cells
to UVA was confirmed by clonal survival. A combination
of 100 Amol/L of S4TdR and 10 kJ/m2 of UVA reduced the
survival of both cell types by >99% (Fig. 2B, top). S4TdR
(V300 Amol/L) or UVA (V20 kJ/m2) alone had no effect. The
sensitivity of HT1080 and RTS3b cells to S4TdR/UVA
treatment mirrors that previously reported for SV40-trans-
formed MRC5VA human fibroblasts and Raji lymphoma
cells (26), indicating that the synergy between the drug and
UVA is a general phenomenon.
The S4TdR/UVA sensitivity of NHK and NHF was
measured in the same way. At low S4TdR concentrations
(30 Amol/L; ref. 10), their UVA sensitivity was similar to
that of the two established cell lines (Fig. 2B, bottom).
Higher UVA doses and higher S4TdR concentrations had
significantly less effects on the primary keratinocytes and
fibroblasts suggesting that incorporation of S4TdR into the
Figure 2. Sensitivity of human skin cells to UVA alone and to S4TdR/
UVA assessed by clonal survival assay. A, HT1080, RTS3b, NHK, and
NHF cells were plated at single colony density, and irradiated with UVA
alone (0, 10, 50, 100, 200, and 500 kJ/m2). B, cells were treated with 0,
10, and 100 Amol/L of S4TdR (gray, black , and white symbols,
respectively) as indicated in Materials and Methods, then plated at single
colony density, and UVA-irradiated at 0, 5, 10, and 20 kJ/m2. Colonies
were stained and counted after 10 to 14 days. All curves were determined
from at least three independent experiments, each done in triplicate. Top,
HT1080 cells were compared with RTS3b. Bottom, normal human
keratinocytes (NHK ) were compared with their patient-matched fibroblasts
(NHF ). Points, means; bars, SD (n = 4–6).
Figure 1. Survival of human fibrosarcoma and keratinocyte lines
following S4TdR/UVA treatment. HT1080 and RTS3b cells were treated
with 0, 10, 30, or 100 Amol/L of S4TdR for 48 h as described in Materials
and Methods, and UVA- or UVB-irradiated at the doses indicated. Cells
were grown further for 72 h in fresh medium and survival was measured by
dimethylthiazol-2-yl-2-5-diphenyltetrazolium bromide assay. Columns,
means; bars, SD (n = 4–6). UVA treatments: *, P < 0.05; **, P <
0.01, significant differences from the corresponding drug treatment in
unirradiated control. Survival associated with UVB treatments were not
significantly different among themselves, but were significantly different
(P < 0.05) from the corresponding drug treatment in unirradiated controls.
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DNA may be limiting. This is consistent with the
measurably lower S phase fraction in these primary cells.
There was no significant difference in the survival
responses of NHK, NHF, or psoriatic human fibroblast to
S4TdR/UVA (data not shown).
Morphologic Changes Following S4TdR/UVA
Microscopic inspection indicated that as early as 24 h after
irradiation with 10 kJ/m2 of UVA, HT1080 cells grown in
100 Amol/L of S4TdR exhibited the membrane blebbing and
cell fragmentation that are typical of apoptosis (Fig. 3A).
Cells treated with UVA or S4TdR alone seemed normal.
Induction of cell death was examined by flow cytometry 24
h after treatment. Representative Annexin V versus PI
scatter plots are shown in Fig. 3B . Twenty-four hours after
a combination of 10 kJ/m2 of UVA and 100 Amol/L of
S4TdR, f40% of HT1080 cells were undergoing apoptosis
(Annexin V–positive), consistent with the morphologic
changes observed microscopically. A kinetics experiment
(Supplementary Fig. S1) 4 documented the sequential
conversion of Annexin V–positive/PI-negative cells to
Annexin V–positive/PI-positive cells, recorded at 16 and
24 h. Events in S4TdR/UVA-treated RTS3b cells were
essentially the same (Fig. 3B). Neither UVA nor S4TdR
alone induced significant changes in the pattern of staining.
These findings confirm that S4TdR plus low-dose UVA
treatment causes cell death to similar extents in HT1080
and RTS3b, and further indicates that death occurs by
apoptosis.
The induction of apoptotic HT1080 cells inferred from
microscopic observation and Annexin V/PI staining was
confirmed by analysis of key apoptosis proteins. S4TdR/
UVA treatment induced cleavage of caspase 3, the
Figure 3. S4TdR/UVA treatment induces cell death by apoptosis. HT1080 and RTS3b cells were treated with S4TdR or UVA or combinations as
indicated. A, 24 h posttreatment, bright-field images were captured (magnification, 200). Cellular damage (arrows ): shrinkage, rounding up and
fractionating into several bodies indicative of cell death by apoptosis are visible only when S4TdR and UVA are used in combination. B, cells treated as
described in A, were processed for flow cytometry analysis by double staining with Alexa647-conjugated Annexin V and PI, as described in Materials and
Methods. Apoptotic cells were considered as the sum of Annexin V-positive/PI-negative (early apoptotic) and Annexin V-positive/PI-positive (late
apoptotic) cells. C, extracts from HT1080 cells treated as in A, were assayed by Western blot and probed with antibodies against cleaved forms of
caspase-3 and against total Bak (top). HT1080 cells treated as in A, were processed for the detection of the active form of Bak, as referred to in Materials
and Methods (bottom ). Isotype, control sample incubated with an isotype-matched irrelevant antibody. Cells were judged positive for the detection of the
active form of Bak by setting a marker on isotype control. Columns, means from Bak-associated fluorescence; bars, SD (n = 4). The ‘‘S4TdR/UVA’’
treatment value was significantly different (P < 0.05) from the values for ‘‘no UV’’, ‘‘S4TdR’’, and ‘‘UVA’’ treatments.
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executioner caspase (Fig. 3C, top). In addition, flow
cytometry analysis indicated that f60% of S4TdR/UVA-
treated HT1080 cells were positive for an active form of
Bak generated by a conformational change that follows
the induction of apoptosis (Fig. 3C, bottom ; Supplementary
Fig. S2;4 refs. 33, 34). Less than 5% of cells treated with
S4TdR or UVA alone were Bak isoform–positive. S4TdR/
UVA treatment did not induce a significant change in the
steady-state level of Bak protein, however (Fig. 3C, top).
This indicates that events following S4TdR/UVA treatment
differ from those following UVB radiation (19).
p53 DNADamage Response
The p53 response was examined in HT1080 cells. UVA
doses <50 kJ/m2 did not induce p53 stabilization (data not
shown). At doses in excess of 100 kJ/m2, p53 stabilization
was rapid and was detectable as early as 2 h postirradia-
tion. p53 levels remained high for at least 24 h after
irradiation. Extremely high UVA doses consistently abro-
gated the response, and after 500 kJ/m2, no p53 was
detectable by Western blotting until at least 16 h postirra-
diation. But this dose was very toxic, as shown previously
in Fig. 2A . The levels of a-tubulin, included as a loading
control, were also severely reduced by this dose, indicating
that reduced p53 expression may be a consequence of an
inhibition of transcription/translation or general cell
killing and proteolysis. Cells recovered from this inhibi-
tion, partial recovery was apparent at 16 h after irradiation,
and by 24 h, both p53 and a-tubulin levels had increased
significantly (Fig. 4A).
In contrast, very low doses of UVA (10 kJ/m2) induced
p53 stabilization in cells pretreated with S4TdR, consistent
with the formation of photochemical DNA damage.
Induction was rapid and increased p53 protein levels were
detectable 2 to 4 h after radiation (Fig. 4B). The response
seemed to be maximal at 16 to 24 h.
HPVE6, the p53 Response, and Cell Death
E6 proteins of diverse HPV types protect HT1080 cells
against UVB-induced apoptosis (16). To investigate whether
HPV E6 influences the induction of p53 response and cell
death by S4TdR/UVA, we constructed HT1080 cells stably
expressing E6 from high-risk HPV5 (an epidermodysplasia
verruciformis–associatedHPV)orHPV18 (ananogenital type).
Neither S4TdR/UVA (Fig. 5A) nor UVB treatment (data
not shown) induced detectable p53 stabilization in HT1080
cells expressing HPV18 E6. As expected, this compromised
downstream events and the induction of both cyclin-
dependent kinase inhibitor p21CIP1 and E3 ubiquitin ligase
Mdm2 was also abrogated in HPV18 E6–expressing cells.
In contrast, p53 stabilization seemed to be normal in
HT1080 cells expressing HPV5 E6, which were comparable
to the vector-only control cells in this regard. p53
stabilization was accompanied by Ser392 and Ser15 phos-
phorylation—both of which are associated with DNA
damage and are required for p53 functions (35, 36). p21
Figure 4. The p53 response to UVA and S4TdR/UVA treatment in
HT1080 cells. Cells were treated as indicated on the figures and detailed in
Materials and Methods. A, irradiation with UVA alone. B, treatment with
100 Amol/L of S4TdR or 10 kJ/m2 of UVA alone or in combination, or with
0.15 kJ/m2 of UVB, and then assayed by Western blot and probed for
activation of p53. Blotting for the cytoskeleton protein a-tubulin was used
as a loading control.
Figure 5. The p53 response in HT1080 sublines expressing HPV5 E6 or
HPV18 E6. A, HT1080 sublines were treated without or with S4TdR/UVA
as detailed in Materials and Methods. At 24 h posttreatment, total cell
protein extracts were resolved on SDS-PAGE gel and probed for the
proteins of interest. B, a fraction of the cells treated under A were also
analyzed for apoptosis by Annexin V/PI staining followed by flow
cytometry. Columns, mean percentages of Annexin V–positive cells are
represented for each subline; bars, SD (n = 4). S4TdR/UVA treatment
gave a significant increase of Annexin V (P < 0.05) over unirradiated
controls within each cell line. Identical conditions compared across the
lines were not significantly different.
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and Mdm2 induction in HPV5 E6–expressing cells was
also comparable to vector-only controls. Consistent with
their lack of cytotoxicity at these doses, neither S4TdR nor
UVA alone had any effect on the induction or stabilization
of these proteins (data not shown).
Expression of HPV18 E6, but not HPV5 E6 reduced the
basal level of the proapoptotic Bax protein (Fig. 5A).
S4TdR/UVA had no detectable effect on Bax levels which
remained unaltered 24 h after treatment of control, HPV5
E6, or HPV18 E6 cells. Levels of the ubiquitin ligase E6AP,
which is responsible for the degradation of p53 in cells
expressing E6 from anogenital type HPVs (37), were also
not significantly altered 24 h after S4TdR/UVA treatment.
Notwithstanding their effects on gene expression, neither
HPV5 E6 nor HPV18 E6 detectably altered the resistance
of HT1080 cells to S4TdR/UVA. This was apparent
in measurements of apoptosis by Annexin V/PI staining
(Fig. 5B) and was confirmed by measurements of viability
by dimethylthiazol-2-yl-2-5-diphenyltetrazolium bromide
assay at 72 h posttreatment (data not shown) and clonal
survival (Fig. 6). Because both the HPV5 and HPV18
E6 proteins protect HT1080 cells against killing by UVB,
these observations provide additional evidence that
S4TdR/UVA and UVB activate different cell death
pathways.
Discussion
The synergistic cytotoxicity of S4TdR and UVA was
previously shown to require incorporation of the thiopyr-
imidine into DNA via the thymidine salvage pathway (26).
S4TdR-treated cells are killed by extremely low UVA
doses—well below those required to cause death or
mutation if given without the sensitizer. This suggested
that it might be worth evaluating S4TdR/UVA as a
potential treatment strategy for tumors or hyperprolifer-
ative disorders that are accessible to therapeutic radiation.
The present investigation into the effects of S4TdR/UVA on
a series of established and primary cells derived from skin
represents a first step.
Overall, despite differences after UVA treatment alone,
the response of these various cell types to combined
S4TdR/UVA is quite uniform. The sensitivity of the
established HT1080 and RTS3b cell lines did not differ
significantly from that previously reported for the estab-
lished SV40-transformed human fibroblast cell line
MRC5VA. A marked resistance of primary keratinocytes
and fibroblasts—particularly at higher S4TdR concentra-
tions—is consistent with their reduced proliferative frac-
tion and use of a UVA chromophore that depends on
incorporation into DNA for its biological effect. Differences
in response to UVA alone were more marked and we
confirmed the relative resistance of NHK to UVA (32).
Their increased ability to withstand high UVA doses is not
paralleled by S4TdR/UVA resistance. This suggests that the
death pathways engaged after UVA and S4TdR/UVA are
likely to be different.
Cellular utilization of exogenous thymidine analogues is
influenced by both the intracellular pool of thymidine
nucleotides produced by de novo synthesis and the
extracellular concentration of competitor TdR. The calf
serum used for cell culture may contain high concentra-
tions of TdR, so to obtain consistent results with S4TdR,
serum was dialyzed before use. Human serum also
contains TdR. At V0.1 Amol/L (38), the human plasma
TdR concentration is orders of magnitude lower than that
of calf serum, however. This suggests that, if reasonable
serum levels of S4TdR could be achieved in human subjects,
good cellular uptake and incorporation of the analogue are
likely. The reported serum TdR concentration in mice is
significantly higher, f1 Amol/L (39). The possibility that
this higher concentration of competitor nucleoside might
attenuate the effects of S4TdR merits consideration if mouse
models or human xenografts are used to evaluate S4TdR/
UVA as a therapeutic option.
The aim of anticancer treatments is to destroy the tumor
cells with minimal effects on healthy surrounding tissue.
In the case of S4TdR/UVA, the requirement for active
thymidine salvage and DNA replication as well as precise
targeting of the UVA would both favor the selective
destruction of tumor tissue. Our findings that the two
established transformed skin-related cell lines were more
susceptible to S4TdR/UVA than primary keratinocytes
and fibroblasts with a lower proliferative fraction is in
line with this. It is noteworthy, in this regard, that SCCs
Figure 6. Survival of HT1080 sublines expressing E6 from HPV5 or
HPV18 to S4TdR/UVA treatment, measured by colony-forming assay.
Cells were treated with 0, or 10, 100 Amol/L of S4TdR as detailed in
Materials and Methods, then plated at single colony density, and UVA-
irradiated at 0, 5, 10, and 20 kJ/m2. Surviving colonies were counted after
10 to 14 days. All curves were determined from at least three independent
experiments, each done in triplicate. There were no significant differences
in cell-killing at the UVA doses used, when comparing the HPV lines to the
vector control line.
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are generally characterized by a high proliferative fraction
and exhibit strong staining with proliferation-associated
markers such as Ki-67 (40), and often show invasive
properties. Interestingly, HPV-positive SCCs also have a
high proliferative potential, but show a significantly
lower level of apoptosis than HPV-negative SCCs (41).
Hence, our findings suggest that S4TdR/UVA might be
particularly effective in treating SCCs independently of
their HPV status. In contrast, basal cell carcinomas—
which are generally slow growing—would be expected to
be less responsive to S4TdR/UVA.
Despite high proliferation rates and a potential sensitivity
to DNA-damaging drugs, the effectiveness of therapeutic
treatments can be compromised by down-regulation or
inactivation of death pathways in tumor cells. One example
is the resistance to DNA-damaging therapeutics that often
accompanies p53 inactivation. p53 mutations are very
common among NMSCs (24, 25). One significant finding
of our study is that the S4TdR/UVA sensitivity of the p53
wild-type HT1080 and p53-null RTS3b cells are similar.
Although S4TdR/UVA treatment induced p53 stabilization
and downstream components of the p53 DNA damage
response, its toxicity seems to be largely independent of
p53 status.
HT1080 and RTS3b cell lines are not isogenic, however,
and any extrapolation of findings derived from compar-
isons between them should be made with caution. The
behavior of HT1080 clones expressing E6 proteins
derived from different oncogenic HPVs provides a more
appropriate comparison of the effects of p53 inactivation.
These experiments provide additional evidence that
S4TdR/UVA cytotoxicity is largely independent of p53
status. Neither HPV18 E6, from an anogenital HPV type
known to target p53 for destruction (11), nor HPV5,
associated with NMSC in patients with epidermodyspla-
sia verruciformis, which does not promote p53 degrada-
tion (16), significantly affected S4TdR/UVA-induced cell
death.
Our findings raise the question of the nature of the
DNA lesions introduced by S4TdR/UVA and the DNA
damage response that they provoke. Based on chemical
evidence and the relative sensitivity of xeroderma
pigmentosum cell lines to S4TdR/UVA, we have sug-
gested that S4TdR/UVA produces thietane lesions (42)
that resemble the (6-4)pyrimidine-pyrimidone adducts
produced by UVC (and UVB) radiation, and that these
contribute to cytotoxicity (26). The differential effect of
HPV E6 status on UVB and S4TdR/UVA-mediated
apoptosis suggests that alternative DNA lesion(s) might
be the key to S4TdR/UVA toxicity. In agreement with
this possibility, DNA damage produced by S4TdR/UVA
is not recognized by antibodies that recognize UVB-
induced (6-4)pyrimidine-pyrimidone photoproducts, and
S4TdR/UVA treatment induces a burst of reactive oxygen
species in the cell nucleus.5 Despite this uncertainty,
the finding that S4TdR/UVA cytotoxicity is independent
of HPV E6 status suggests that this may provide a useful
approach to the treatment of skin disorders in which
there is HPV involvement.
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